Track topics on Twitter Track topics that are important to you
The US anticoagulation therapy market projected to grow at a CAGR of 8.5%.
The US anticoagulation therapy market is projected to reach USD 27.83 billion by 2022 from an estimated USD 18.49 billion in 2017, at a CAGR of 8.5%. The US anticoagulation therapy market is segmented into products anticoagulation drugs, PT/INR testing devices and anticoagulation clinics. The growth of the anticoagulation drugs market is primarily driven by the rising incidence of venous thromboembolism, atrial fibrillation, and stroke; longterm administration and high volume of recurring sales of anticoagulation drugs; and increasing demand for novel oral anticoagulants NOACs. On the other hand, the high cost of NOACs and requirement of significant investments in the development of anticoagulation drugs are the major factors restraining the growth of this market. In addition, the growth of the anticoagulation clinics market is primarily driven by the increasing prevalence of cardiovascular diseases blood disorders, high level of medication adherence associated with clinics, and rising aging population.
The NOACs segment is expected to grow at the highest CAGR during the forecast period.
The anticoagulation therapy market for drugs is categorized into NOACs, warfarin VKA, and other drugs. The NOACs segment is expected to grow at the highest CAGR during the forecast period. Due to the better safety and efficacy of NOACs, as compared to traditional therapies, the adoption of NOACs is higher as compared to traditional drugs. In addition, key market players such as Portola Pharmaceuticals received the FDA approval for its NOACBetrixaban in July 2017 are focusing on the development of NOACs in order to capitalize on the growth opportunities presented by this shift in market dynamics. Consequently, many other companies are also expected to focus on developing more safe and efficient NOACs in the coming years; this will ensure the continued growth of this segment.
By type of clinics, the pharmacybased anticoagulation clinics segment is expected to grow at the highest CAGR during the forecast period.
On the basis of clinics type, the US anticoagulation therapy market for clinics market is categorized into hospitals associated clinics, independent clinics, and pharmacybased clinics. The pharmacybased clinics segment is expected to grow at the highest CAGR during the forecast period. In the US, the number of pharmacybased anticoagulation clinics has increased significantly in the last few years. This due is to the fact that better results are achieved when therapy is managed by expert pharmacists rather than care provided by family physicians. Moreover, the cost of therapy provided by pharmacybased anticoagulation clinics is comparatively lesser than independent and hospital associated anticoagulation clinics which is expected to drive the market for pharmacybased anticoagulation clinics.
Break of primary participants was as mentioned below:
By Company Type Tier 146%, Tier 236% and Tier 318%
By Designation Clevel22%, Director Level45%, Others33%
Market players such as C. H. Boehringer Sohn Germany, BristolMyers Squibb US, Johnson Johnson US, Pfizer US, Daiichi Sankyo Japan, and Portola Pharmaceuticals US are the major market players in the US anticoagulation therapy market for drugs while Roche Switzerland, Abbott US, Siemens Germany, Alere US, and CoaguSense US are the major market players in the US anticoagulation therapy market for PT/INR home testing devices.
The US anticoagulation therapy market in this report is segmented by products and clinics. It provides detailed information regarding major factors influencing the growth market drivers, restraints, and industryspecific opportunities. The study tracks and analyzes competitive developments such as new product developments and RD activities and profiles the key players in the US anticoagulation therapy market.
Reasons to buy this report:
From an insight perspective, this research report has focused on various levels of analysismarket share of NOACs, company profiles, emerging and highgrowth segments of the US anticoagulation therapy market; market drivers, restraints, and opportunities. The report provides the latest reimbursement trends for PT/INR testing, revenue structure, business models of anticoagulation clinics and indepth impact analysis of NOACs on anticoagulation clinics, allowing buyers to identify the high growth product segment and potential customers and suppliers hence driving revenue growth and profitability.
The report provides insights on the following pointers:
Market Penetration: Comprehensive information on anticoagulation therapy solutions offered by the top players in the US anticoagulation therapy market
Product Development/Innovation: Detailed insights on upcoming technologies, research development activities, and new product launches in the US anticoagulation therapy market
Market Diversification: Exhaustive information about new products, recent developments, and investments in the US anticoagulation therapy market
Competitive Assessment: Indepth assessment of market shares, strategies, products, and manufacturing capabilities of the leading players in the US anticoagulation therapy market
Original Article: US Anticoagulation Therapy Market by Product Anticoagulants Drugs NOACs, Warfarin, PT/INR Devices InOffice, Home Testing, Service Type Testing Consulting, Type of Clinic Hospital Associated, Independent Pharmacybased Forecast to 2022 [Report Updated: 0NEXT ARTICLE
Women's Health - key topics include breast cancer, pregnancy, menopause, stroke Follow and track Women's Health News on BioPortfolio: Women's Health News RSS Women'...
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...